Figure 3.

Expression level of intracellular interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α) were reduced by treatment with anti-CD2 and anti-NKG2D monoclonal antibodies (mAbs). Interleukin-2 (IL-2)-activated human primary natural killer (NK) cells were pre-incubated with designated mAbs as shown on the right and then co-incubated with MPN3 cells. Intracellular IFN-γ (a) and TNF-α (b) were detected in CD56⁺ NK cells. The values represent percentages of CD56⁺ IFN-γ⁺ or CD56⁺ TNF-α⁺ cells, which are representative of five independent experiments.